SpaceOAR® Hydrogel is a clinically proven, minimally invasive spacer designed to minimise the long-term urinary, sexual and bowel side effects and protect quality of life for prostate cancer patients undergoing radiotherapy.
This hydrogel has been designed to reduce radiation exposure to the organs surrounding the prostate. It does this by creating a space between the prostate and the rectum, preventing radiation from reaching healthy tissue in the rectum and maximising the dose to the affected prostate gland.
The hydrogel solution is injected through a minimally invasive procedure that temporarily positions the rectal wall away from the prostate during radiotherapy treatment. The gel remains in place for three to six months after which it is naturally absorbed by the patient’s body.
SpaceOAR® Hydrogel has been implanted in over 50,000 patients worldwide. A three-year evaluation of the treatment results shows it to be safe and effective – with patients displaying a significant reduction in rectal toxicity from radiation and a reduction in urinary symptoms after 15-37 months. Men who were sexually potent at the time of diagnosis were also more likely to avoid loss of sexual function after radiotherapy when they received the SpaceOAR® treatment.
We are the first hospital in the Republic of Ireland to use this technology and the procedure is now offered to suitable patients undergoing radiotherapy for prostate cancer.
Patients who wish to find out more about SpaceOAR® hydrogel technology and procedure can contact the Mater Private Cancer Centre by calling 01 885 8562 or emailing email@example.com